Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

Reported Earlier, Enliven To Present New ELVN-001 Blood Cancer Trial Data At September Medical Meeting

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company

William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating.

Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78

Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $78.

Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint.

Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events

Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of

A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths

Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.